Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Last $34.01 USD
Change Today -0.19 / -0.56%
Volume 5.5K
HLUKF On Other Exchanges
As of 5:20 PM 02/11/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Ottiliavej 9

Valby, 2500


Phone: 45 36 30 13 11

Fax: 45 36 30 19 40

H. Lundbeck A/S, a pharmaceutical company, engages in the research and development, production, marketing, and sale of pharmaceuticals for the treatment of CNS disorders, including depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease and insomnia. The company’s products include Circadin for the treatment of primary insomnia; Cipralex, Lexapro, Sipralexa, Sipralex, Cipramil, Seropram, Cipram, and Celexa for the treatment of depression, generalized anxiety disorder, panic disorder, and social anxiety disorder; Ebixa and Ebix for the treatment of moderate to severe Alzheimer’s disease; Azilect for the treatment of Parkinson’s disease; Serdolect and Serlect for the treatment of schizophrenia; and Deanxit for the treatment of mild depression. The company also offers Noritren, Nortrilen, Sensaval, Saroten, Sarotex, and Redomex for depression; and Cisordinol and Clopixol to treat schizophrenia and other psychotic disorders, anxiety, restlessness, and insomnia. The company provides Cisordinol Depot, Clopixol Depot, Ciatyl-Z Depot, Fluanxol Depot, and Depixol to maintain and treat chronic psychotic disorders; and Cisordinol-Acutard, Clopixol-Acutard, Clopixol-Acuphase, and Ciatyl-Z-Acuphase for treating acute psychotic episodes and exacerbation of psychotic disorders. Its other products include Fluanxol, Fluanxol Mite, and Depixol for schizophrenia, other psychotic disorders, and mild depression; and Truxal and Truxaletten for the treatment of schizophrenia and other psychotic disorders, anxiety, restlessness, and withdrawal symptoms in drug addicts. The company has a range of products under clinical development for the treatment of mood disorders, psychoses, neurodegenerative disorders, epilepsy, sleep disorders, and stroke. Partnerships The company has partnership with BioTie Therapies Corp.; Forest Laboratories, Inc.; Merz Pharmaceuticals GmbH; Mochida Pharmaceutical Co.; neurim Pharmaceuticals Ltd.; PAIOn AG; Solvay Pharmaceuticals B.V.; Takeda Pharmaceutical Company Ltd.; Teva Pharmaceutical Industries Ltd.; and Xian-Janssen Pharmaceutical Ltd. History H. Lundbeck A/S was founded in 1915.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HLUKF:US $34.01 USD -0.19

HLUKF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.125.20 CHF -3.70
Ipsen SA €47.55 EUR -1.59
Lupin Ltd 1,791 INR -61.80
Meda AB kr143.90 SEK +57.85
Recordati SpA €20.48 EUR +0.17
View Industry Companies

Industry Analysis


Industry Average

Valuation HLUKF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.2x
Price/Book 5.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.8x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact H LUNDBECK A/S, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at